文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > Umbilical Cord-Derived Mesenchymal Stem Cells Isolated
侵权投诉

Umbilical Cord-Derived Mesenchymal Stem Cells Isolated

Stem cells transplantation holds great promise for the treatment of ischemic diseases through functional revascularization. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) are also an ideal candidate for cell-based bioengineering. Herein, we report on the development of a simple and effective protocol to isolate UC-MSCs, and confi rm their endothelial potential both in vitro

STEM CELLS AND DEVELOPMENTVolume 19, Number 10, 2010© Mary Ann Liebert, Inc.DOI: 10.1089/scd.2009.0321

Umbilical Cord-Derived Mesenchymal Stem Cells Isolated

by a Novel Explantation Technique Can Differentiate into Functional Endothelial Cells and Promote Revascularization

1Yan Xu ,1, * Hengxing Meng ,2, * Changhong Li ,1 Mu Hao , Yafei Wang ,1 Zhen Yu ,1 Qian Li ,1,2 Junling Han ,1,2

1,2

Qiongli Zhai ,3 and Lugui Qiu

Stem cells transplantation holds great promise for the treatment of ischemic diseases through functional revascu-larization. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) are also an ideal candidate for cell-based

bioengineering. Herein, we report on the development of a simple and effective protocol to isolate UC-MSCs, and confi rm their endothelial potential both in vitro and in vivo. UC-MSCs were isolated by a novel explanta-tion technique and induced to differentiate into endothelial-like cells. Then UC-MSCs were transplanted into ischemic mouse model and cultured on 3D gel/MMT-CS composite scaffolds. Morphological and prolifera-tion assessments show that suffi cient UC-MSCs can be generated during a relatively short culture period with explantation technique. Increased expression of endothelial-specifi c markers (KDR and vWF), and functional markers (ac-LDL uptake and UEA-1 binding), indicate that functional endothelial progenitor cells are induced after 9 days of in vitro culture. In an ischemic hindlimb mouse model, the ratio of ischemic/nonischemic limb perfusion 4 weeks after MSCs transplantation reached 0.84 ± 0.09. The capillary density of this group was 2.57-fold greater than that of sham-injected mice ( P < 0.05). Immunofl uorescence and immunohistological analy-ses indicate that MSCs may act to salvage the ischemic tissue by incorporating into the local vasculature. In vitro, UC-MSCs were observed to incorporate into 3D gel/MMT-CS composite scaffolds, to secrete extracellular matrix, to remain viable, and to retain their proliferation capacity. In conclusion, UC-MSCs isolated by novel yet simple explantation technique are well suited for application in the development of novel stem cell-based revas-cularization therapies.

Introduction

schemic diseases, such as coronary artery disease and peripheral vascular disease, are becoming an increasingly signifi cant problem in terms of morbidity, mortality, and healthcare cost in most countries. The available treatment options for advanced-stage patients are generally limited to angioplasty, balloon dilatation, and other palliative inter-ventions, but many patients with moderate-to-severe isch-emic disease cannot benefi t from such interventions. One possible solution for such patients would involve transplan-tation of a preformed primitive vascular plexus, produced ex vivo by tissue engineering [ 1 ].

I

or a long time, research into ischemia reduction has con-F

centrated on 2 distinct types of vessel growth—angiogene-sis and arteriogenesis. Endothelial cells are key participants in these processes of vessel growth and tissue regenera-tion. Unfortunately, the proliferative capacity of mature endothelial cells is limited, making it necessary to discover alternative cellular sources for autologous and allogeneic use. Human mesenchymal stem cells (MSCs) possess the potential for both powerful ex vivo expansion and versatile differentiation, which places them at the forefront in the fi eld of stem cell-based transplantation and therapy [ 2–4 ]. Although bone marrow (BM) is the most common source of MSCs [ 2 , 5 ], in recent years many groups have turned their

Institute of Hematology & Hospital of Blood Diseases, State Key Laboratory of Experimental Hematology, Chinese Academy of

Medical Sciences & Peking Union of Medical College, Tianjin, People’s Republic of China.

2 Tianjin Cord Blood Bank of National Research Center for Stem Cell Engineering and Technology, Tianjin, People’s Republic of China. 3

Department of Pathology, Tianjin Medical University Cancer Hospital, Tianjin, People’s Republic of China. *These authors contributed equally to this work.

1

1511

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email